Gilead Sciences, Inc. (Nasdaq: GILD) will present new research that reinforces its commitment to advancing innovation for ...
In recent weeks, Gilead Sciences announced Health Canada's conditional approval of LYVDELZI (seladelpar) for primary biliary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback